2023-08-08 10:48:40 ET
- PepGen press release ( NASDAQ: PEPG ): Q2 GAAP EPS of -$0.82.
- Cash and cash equivalents were $147.0 million as of June 30, 2023, which is anticipated to fund currently planned operations into early 2025.
- Research and Development expenses were $16.9 million for the three months ended June 30, 2023, compared to $14.2 million for the same period in 2022.
- General and Administrative expenses were $4.2 million for the three months ended June 30, 2023, compared to $3.4 million for the same period in 2022.
- Net loss was $19.5 million for the three months ended June 30, 2023, compared to $17.3 million for the same period in 2022. PepGen had approximately 23.8 million shares outstanding on June 30, 2023.
For further details see:
PepGen GAAP EPS of -$0.82